EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioHarvest Sciences's EBITDA for the
three
months ended in Mar. 2026 was $-1.29 Mil. BioHarvest Sciences's Revenue for the
three
months ended in Mar. 2026 was $8.51 Mil. Therefore, BioHarvest Sciences's EBITDA margin for the quarter that ended in Mar. 2026 was -15.19%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioHarvest Sciences EBITDA Margin % Related Terms
BioHarvest Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BioHarvest Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BHST vs GWLL, CLNN, FTLF: EBITDA Margin % Comparison
For the Packaged Foods subindustry, BioHarvest Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioHarvest Sciences EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioHarvest Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioHarvest Sciences (BHST) has a EBITDA Margin % of -15.19% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioHarvest Sciences and its competitors. According to the industry distribution chart, BioHarvest Sciences ranks #1816 out of 1953 companies in the Consumer Packaged Goods industry, placing it in the top 93%.
Is BioHarvest Sciences' EBITDA Margin % too high?
BioHarvest Sciences' current EBITDA Margin % is -15.19%. Based on the distribution chart, BioHarvest Sciences ranks #1816 out of 1953 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, BioHarvest Sciences has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' EBITDA Margin % compare to GWLL and CLNN?
According to the Consumer Packaged Goods industry distribution chart, BioHarvest Sciences ranks #1816 out of 1953 companies for EBITDA Margin %. This places BioHarvest Sciences in the lower half of its industry. The industry median EBITDA Margin % is 8.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.99, based on 1,953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioHarvest Sciences and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioHarvest Sciences's current EBITDA Margin % is -15.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.57, compared to a current price of $2.77 — trading 67.7% below its estimated fair value. The current EBITDA Margin % is -15.19%. BioHarvest Sciences' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current EBITDA Margin % is -15.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioHarvest Sciences (BHST) Overvalued in 2026?
Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued.
The current stock price of $2.77 is trading 67.7% below its estimated GF Value™ of $8.57.
GuruFocus considers BioHarvest Sciences to be Possible Value Trap.
Key valuation signals for BHST:
EBITDA Margin %: -15.19%
GF Value™: $8.57 vs. price of $2.77 (67.7% below fair value)
No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
64GF Score
Get the complete analysis for BHST
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHST has been successfully added to your 
